Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Purpose: Interleukin-6 (IL-6) is a key inflammatory mediator in the pathogenesis of uveitic macular oedema (UMO), a visionthreatening complication of non-infectious uveitis.Vamikibart is a recombinant, humanised, intravitreal (IVT), monoclonal anti-IL-6 antibody.Methods: MEERKAT (MK; NCT05642312; N = 245) and SANDCAT (SC; NCT05642325; N = 256) are identical global phase 3 trials evaluating the efficacy and safety of IVT vamikibart (0.25 mg, 1.0 mg, vs. sham; 1:1:1; 4Â monthly then PRN to W48) in patients with non-infectious uveitis-UMO.Results: Vamikibart showed clinically meaningful efficacy vs. sham at W16. Proportion of patients with !15-letter improvement in best-corrected visual acuity for MK/SC: 26.1/34.0%0.25 mg, 43.2/24.2%1.0 mg vamikibart vs. 6.3/13.3%sham.Mean change from baseline best-corrected visual acuity for MK/SC: +9.6/11.9letters 0.25 mg, +12.8/9.2 letters 1.0 mg vamikibart vs. +3.5/5.0 letters sham.Mean change from baseline CST for MK/SC: -187.5/-209.7 μm 0.25 mg, -196.1/-194.7 μm 1.0 mg vamikibart vs. -58.5/-43.5 μm sham.Vamikibart was well tolerated; serious ocular AE incidence was low.Conclusion: Vamikibart, a novel IVT anti-IL-6 therapy, was efficacious and well-tolerated in patients with UMO.
DOI: 10.1111/ceo.70047
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7130592904
FWCI:
Cites:
Cited by:
Related to: